The high frequency of T regulatory cells in patients with B-cell chronic lymphocytic leukemia is diminished through treatment with thalidomide
Open Access
- 26 July 2007
- journal article
- letter
- Published by Springer Nature in Leukemia
- Vol. 22 (1) , 222-224
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Low-dose thalidomide in combination with oral fludarabine and cyclophosphamide is ineffective in heavily pre-treated patients with chronic lymphocytic leukemiaLeukemia Research, 2007
- TNF downmodulates the function of human CD4+CD25hi T-regulatory cellsBlood, 2006
- FOXP3: Of Mice and MenAnnual Review of Immunology, 2006
- CD4(+)CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancersCancer Immunology, Immunotherapy, 2005
- Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL)Blood, 2005
- Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabineBlood, 2005
- Immune defects in patients with chronic lymphocytic leukemiaCancer Immunology, Immunotherapy, 2005
- New pharmacokinetic and pharmacodynamic tools for interferon-alpha (IFN-?) treatment of human cancerCancer Immunology, Immunotherapy, 2004
- The clinical significance of tumor necrosis factor-α plasma level in patients having chronic lymphocytic leukemiaBlood, 2002